Annovis Bio, Inc.
ANVSAnnovis Bio, Inc. (ANVS) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and neurological disorders. The company's research emphasizes novel small-molecule therapeutics aimed at addressing underlying disease mechanisms in conditions such as Alzheimer's disease, Parkinson's disease, and other central nervous system disorders. Annovis Bio aims to advance treatments that can potentially improve cognitive function and slow disease progression.
Company News
Annovis Bio will present two research presentations at the CTAD conference, highlighting biomarker data for buntanetap in treating Alzheimer's and Parkinson's diseases, focusing on potential disease-modifying therapeutic approaches.
The Alzheimer's disease market is expected to grow significantly between 2025-2034, driven by emerging therapies targeting disease mechanisms and improved diagnostic capabilities, with the US market representing approximately 50% of the total market size.
Annovis Bio, a late-stage clinical drug platform company, will present data from its latest Phase 3 Parkinson's disease and Phase 2/3 Alzheimer's disease studies at the AD/PDâ„¢ 2025 conference in Vienna.
LEQEMBI, an Alzheimer's disease treatment developed by Biogen and Eisai, has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. The Alzheimer's disease market is highly competitive, with numerous companies advancing therapies in the pipeline.
The article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical tr...
